Physician profile
Harley W Yoder
NPI 1821199431
$2,113.24
in general payments reported to CMS, 2019-2025
13 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.84 · 2020: $125 · 2021: $120 · 2022: $119 · 2023: $506 · 2024: $405 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.77 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $621.55 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $481.68 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $213.06 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.64 | 2021-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Boston Scientific Corporation | $120.37 | 2023 | Watchman Access System |
| Glaxosmithkline, LLC. | $112.10 | 2023 | Arexvy |
| Phathom Pharmaceuticals, INC. | $89.26 | 2024 | Voquezna |
| Viatris Specialty LLC | $79.32 | 2025 | Yupelri |
| Medtronic, INC. | $72.05 | 2025 | |
| Axsome Therapeutics, INC. | $23.27 | 2025 | Symbravo |
| Regeneron Healthcare Solutions, INC. | $23.26 | 2023 | Dupixent |
| Abbvie INC. | $13.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harley Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.